Google Alert - dupilumab

JAK-1 Inhibition With Upadacitinib Reduces Systemic Inflammation in AD, With Potential ...

about 16 hours ago

Head-to-head findings indicated upadacitinib 30 mg achieved greater hs-CRP and eosinophil reductions...

Abrocitinib nella dermatite atopica: rapidità d'azione, controllo - Pharmastar

about 17 hours ago

Per la dermatite atopica, invece, il vero cambiamento è arrivato soltanto nel...

Dupilumab Improves Esophageal Distensibility in Eosinophilic Esophagitis

about 19 hours ago

Dupilumab is an FDA-approvedopens in a new tab or window monoclonal antibody...

FDA Approves Dupixent for Chronic Spontaneous Urticaria in Young Children

1 day ago

The FDA has approved Dupixent (dupilumab) for the treatment of children (aged...

Dupilumab vs Swallowed Steroids Reduces Symptoms and Health Care Utilization in EoE

1 day ago

Gastroenterology Advisor (@Gastro_Advisor). 34 views. Dupilumab is associated with improved symptom-related outcomes...

ဒူပီလူမတ် | အပိုလိုဆေးရုံများ - Apollo Hospitals

1 day ago

မိတ်ဆက်- Dupilumab ဆိုတာဘာလဲ။ Dupilumab သည် monoclonal antibodies များဟုလူသိများသော ဆေးဝါးအမျိုးအစားတွင်ပါဝင်သော ဆရာဝန်ညွှန်ကြားချက်ဖြင့်သောက်သုံးရသော ဆေးဝါးတစ်မျိုးဖြစ်သည်။ ၎င်းကို...

Celldex's Phase 3 CSU Trial Enrolls 1,939 Patients Six Months Ahead of Plan

1 day ago

... dupilumab and omalizumab largely leave behind. The more clinically interesting signal...

In a patient with atopic eczema and an IgE level of 6000 IU/mL, what treatment should be given?

1 day ago

Start with dupilumab 600 mg subcutaneously initially, then 300 mg every 2...

April 2026: Notable Drug Approvals - MPR - eMPR.com

1 day ago

Dupixent (dupilumab), Interleukin-4 receptor alpha antagonist, Treatment of chronic spontaneous urticaria (CSU)...

https://www.google.com/url?rct=j&sa=t&url=https://www.hmpgloballearningnetwork.com/flag/flag/save_article/203446/full%3Fdestination%3D/site/thederm/qas/dr-jenny-murase-understanding-dupilumab-treatments%26token%3DeWIJtgk-z0de7T6iUUjTKYwj2JDRpCpptsRZ1uKlEj

2 days ago

Long-term dupilumab shows psychological benefits in atopic dermatitis patients

2 days ago

Dupilumab improves psychological well-being at 52 weeks in moderate-to-severe atopic dermatitis, while...

Reassessing Treatment Outcomes Following Immune-Related Adverse Events | JAMA Oncology

2 days ago

To the Editor The article by Block et al suggests an immediate...